EUVIMEDObjevte EUVIMED
Crossref

The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients

Marc-Elie Nader iD, Jonathan Choi iD, Mike Hernandez iD, Katherine Hutcheson iD, Taylor Myers, Shirin Jivani, Rajarshi Pratihar iD, Katharine Fernandez iD, Jack Phan iD, Chelsea You, Paul W Gidley iD

Otolaryngology–Head and Neck Surgery · 2025

DOI: 10.1002/ohn.1032 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2025. Written by Marc-Elie Nader and 10 co-authors. Institution: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Major MEDLINE topics: Cisplatin, Metformin, Ototoxicity, Antineoplastic Agents. 32 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

Ototoxicity is an important side effect of cisplatin. Recent animal and in vitro studies suggest metformin may protect hearing, though human studies are lacking. We report the first retrospective clinical study exploring the effects of metformin on cisplatin‐induced ototoxicity. Study Design Retrospective case‐control.

Setting

Tertiary‐care center.

Methods

We reviewed all diabetic patients treated with cisplatin who were enrolled in an auditory monitoring program between January 1, 2000 and December 31, 2018. Patients were grouped according to their use of metformin at the time of chemotherapy. Demographics, oncologic diagnosis and treatment, and prior noise exposure were recorded. Audiometric thresholds were compared before and after chemotherapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE). Secondary measures of ototoxicity included changes in hearing using the American Speech‐Language‐Hearing Association (ASHA) and TUNE criteria.

Results

Seventy‐two diabetic patients met the inclusion criteria. Forty‐six patients had taken metformin while on chemotherapy and 26 had not. The proportion of hearing loss as defined by both, CTCAE and ASHA criteria, was more than double in the metformin group relative to the nonmetformin group (CTCAE: 54.4% vs 19.2%, P = .004; ASHA: 62.2% vs 28.0%, P = .003). None of the potential covariates believed to be confounders were significantly associated with the outcome of multivariable analysis.

Conclusion

Contrary to expectations from preclinical data, metformin did not reduce the incidence of hearing loss in patients receiving cisplatin and may, in fact, be associated with an increased risk.

Subjects

MeSH terms (MEDLINE)

CisplatinMetforminOtotoxicityAntineoplastic AgentsHumansMaleRetrospective StudiesFemaleMiddle AgedCase-Control StudiesAgedHypoglycemic AgentsHearing LossDiabetes MellitusAdult

Author keywords

cisplatinhearing lossmetforminototoxicity

Substances

CisplatinMetforminAntineoplastic AgentsHypoglycemic Agents

Authors and institutions

  • Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Austin ENT, Austin, Texas, USA.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Widex US, Weatherford, Texas, USA.
  • Department of Otorhinolaryngology-Head and Neck Surgery, McGovern Medical School, UTHealth Houston, Houston, Texas, USA.
  • National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA.

ORCID profiles: Marc-Elie Nader, Jonathan Choi, Mike Hernandez, Katherine Hutcheson, Rajarshi Pratihar, Katharine Fernandez, Jack Phan, Paul W Gidley

Cite

APA

Nader, M. E., Choi, J., Hernandez, M., Hutcheson, K., Myers, T., Jivani, S., Pratihar, R., Fernandez, K., Phan, J., You, C., & Gidley, P. W. (2025). The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1032

Vancouver

Nader ME, Choi J, Hernandez M, Hutcheson K, Myers T, Jivani S, et al. The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1032

BibTeX
@article{Nader2025,
  author = {Nader, Marc-Elie and Choi, Jonathan and Hernandez, Mike and Hutcheson, Katherine and Myers, Taylor and Jivani, Shirin and Pratihar, Rajarshi and Fernandez, Katharine and Phan, Jack and You, Chelsea and Gidley, Paul W},
  title = {The Effects of Metformin on Cisplatin‐Induced Ototoxicity in Diabetic Patients},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2025},
  doi = {10.1002/ohn.1032}
}
Start for free →